Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Study of Safety, Pharmacokinetics, Pharmacodynamics of Peglamda (Peginterferon Lamda 1) on Healthy Volunteers and the Preliminary Evaluation of Peglamda and Hepasig (Ribavirin) Treatment's Effects on Chronic Hepatitis C Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02063607
Recruitment Status : Completed
First Posted : February 14, 2014
Last Update Posted : December 15, 2016
Sponsor:
Information provided by (Responsible Party):
Nanogen Pharmaceutical Biotechnology Joint Stock Company

Brief Summary:
This is an open label, dose ranging, phase1a/1b clinical trial to study the safety, Pharmacokinetics and Pharmacodynamics of Peglamda 60, 120, 180 and 240 mcg in healthy volunteers and antiviral activity of once weekly Peglamda administration in combination with daily Ribavirin in Hepatitis C naive patients up to 4 weeks period. The objective of the study to establish safety, PK/PD data on healthy subjects and preliminary efficacy and safety in Hepatitis C naive patients.

Condition or disease Intervention/treatment Phase
Hepatitis C Biological: Peginterferon lambda Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Phase 1a/1b Study of Safety, Pharmacokinetics, Pharmacodynamics of Peglamda (Peginterferon Lamda 1) on Healthy Volunteers and the Preliminary Evaluation of Peglamda and Hepasig (Ribavirin) Treatment's Effects on Chronic Hepatitis C Patients
Study Start Date : December 2013
Actual Primary Completion Date : February 2015
Actual Study Completion Date : July 2016

Resource links provided by the National Library of Medicine

Drug Information available for: Ribavirin

Arm Intervention/treatment
Active Comparator: Peginterferon alfa 2a
Peginterferon alfa 2a 180 mcg
Biological: Peginterferon lambda
Experimental: Peginterferon Lambda
Peginterferon Lambda 60,120,180 and 240 mcg
Biological: Peginterferon lambda



Primary Outcome Measures :
  1. Area Under the Concentration-Time Curve (AUC 0-336) [ Time Frame: 0, 6, 12, 24, 36, 48, 72, 96, 120, 144, 168, 216, 264 and 336 hours ]
  2. Percentage of Patients achieving Rapid Virological Response (RVR) [ Time Frame: 4 weeks ]

Secondary Outcome Measures :
  1. Number of subjects with incidence of adverse events [ Time Frame: 15 days ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Phase 1a: The subjects who are willing to participate in Phase 1a study must meet ALL of the following inclusion criteria:

  1. Volunteers (male and female) between the ages of 18-45
  2. Women have a negative pregnancy test result at the time of study.
  3. Clinical examination and result laboratory for 7 days before starting the trial must be inside the normal range.
  4. Currently not following any treatment regimen (except for using the oral contraceptive).
  5. Body mass index is between the range and / or not 25% difference compared to the normal BMI (Appendix 6).
  6. Be able to comply with protocol and exchange information effectively with the researchers, agree on the written informed consent to participate in the clinical trial

Phase 1b: Subjects willing to participate into the phase 1b study must meet ALL of the following inclusion criteria:

  1. Patients with chronic hepatitis C (male and female).
  2. Ages between 18 - 65 years old.
  3. Female patient (or female partners of the male patients) with negative pregnancy test results and/or apply effective contraception if still having sex during the study and for 6 months after using the last dose of Ribavirin.
  4. No previous treatment with IFN or IFN treatment with rapid viral response or already have completely viral response but leave the treatment early.
  5. HCV-RNA levels in serum > 80 IU / mL.
  6. The haematological and biochemical (except ALT / AST) parameters must be within normal limits.
  7. Body weight in the normal range of 25% difference compared to the normal BMI (Appendix 6)
  8. Be able to comply with protocol and exchange information effectively with the researchers, agree on the written informed consent to participate in the clinical trial

Exclusion Criteria:

Phase 1a: Subjects with at least 1 of the following exclusion criteria are considered ineligible to participate in Phase 1a study:

  1. With a history of drug abuse, alcohol or drug using within 1 year before taking part in the clinical trial. AUDIT-C scale (WHO) will be used to assess the use of alcohol. The score ≥ 4 in men or ≥ 3 in women are considered as alcoholics.
  2. History of depression
  3. History of chronic diseases related to the respiratory system, cardiovascular, gastrointestinal, malignant disease affecting to the function of the organ systems. Having any interferon or antiviral therapy within 4 months before the trial
  4. Participate in any clinical trial within 3 months prior the testing
  5. Use of any drug in the last period of relatively positive test which last approximately 6 times the half-life of the drug.
  6. Blood donor with more than 400 mL of blood within 3 months prior the testing
  7. Influenza infection or cold symptoms within 2 weeks before the trial
  8. Having positive tests of HBV, HCV or HIV
  9. Breastfeeding women

Phase 1b: Subjects with at least 1 of the following exclusion criteria are considered ineligible to participate in Phase 1b study:

  1. Co-infection with hepatitis B and/or HIV.
  2. Hepatic Impairment
  3. Cirrhosis
  4. Positive tests with antibody of Peginterferon lambda 1 and Peginterferon alpha 2a.
  5. History of chronic diseases related to the respiratory system, cardiovascular, gastrointestinal, malignant disease affecting to the function of the organ systems.
  6. A history of immune disorders (eg, inflammatory bowel disease, hemorrhagic thrombocythemia, lupus erythematosus, autoimmune hemolytic anemia, autoimmune disease, scleroderma, severe psoriasis, arthritis rheumatoid ...)
  7. A history of severe mental illness, especially depression, especially the serious neurological condition determined as depression or serious psychological disorders, suicidal intention, or being hospitalized for mental illness, or having 1 phase of impaired function due to neuropathy.
  8. A history of severe epilepsy or using antiepileptic drugs.
  9. A history of using anti-cancer agents (including radiation therapy) or immunotherapy (including systematic corticosteroids) within 6 months before using the first testing dose or the patient may be in need of this treatment during the trial
  10. History of organ transplants with the presence of the graft function.
  11. Evidence of alcohol or drugs abuse within 1 year before the trial. AUDIT scale - C will be used to assess the use of alcohol. The score ≥ 4 in men or ≥ 3 in women are considered as alcoholics
  12. History or evidence of severe disease or any other condition based on the investigator assessment that the subject may not be suitable for this study.
  13. Breastfeeding women.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02063607


Locations
Layout table for location information
Vietnam
The Military 108 Hospital
Hanoi, Vietnam, 10000
Sponsors and Collaborators
Nanogen Pharmaceutical Biotechnology Joint Stock Company
Investigators
Layout table for investigator information
Principal Investigator: Dr.Chinh Trong Nguyen, PhD The Military 108 Hospital

Layout table for additonal information
Responsible Party: Nanogen Pharmaceutical Biotechnology Joint Stock Company
ClinicalTrials.gov Identifier: NCT02063607     History of Changes
Other Study ID Numbers: NNG01
First Posted: February 14, 2014    Key Record Dates
Last Update Posted: December 15, 2016
Last Verified: February 2014
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Nanogen Pharmaceutical Biotechnology Joint Stock Company:
Hepatitis C naive

Additional relevant MeSH terms:
Layout table for MeSH terms
Hepatitis
Hepatitis A
Hepatitis C
Hepatitis, Chronic
Hepatitis C, Chronic
Hepatitis, Viral, Human
Liver Diseases
Digestive System Diseases
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Flaviviridae Infections
Ribavirin
Peginterferon alfa-2a
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antiviral Agents
Anti-Infective Agents